For most of the twentieth century, inflammation was thought to resolve passively — once the inciting stimulus disappeared, swelling, pain, and immune infiltration would simply fade. That assumption was wrong. In 2000, Charles Serhan’s laboratory at Harvard demonstrated that resolution is an active, programmed process driven by a new class of lipid mediators biosynthesized from omega-3 fatty acids. These molecules — collectively called specialized pro-resolving mediators (SPMs) — reframe EPA and DHA not as passive anti-inflammatory nutrients but as obligate substrates for an enzymatic resolution program whose failure underlies chronic inflammatory disease.
What Are Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators (SPMs) are a family of endogenous lipid autacoids enzymatically derived from polyunsaturated fatty acids. The principal families include the E-series resolvins (RvE1–RvE3) derived from eicosapentaenoic acid (EPA); the D-series resolvins (RvD1–RvD6), protectins (PD1/NPD1), and maresins (MaR1, MaR2) derived from docosahexaenoic acid (DHA); and lipoxins derived from arachidonic acid. Unlike classical anti-inflammatory drugs, which suppress the initiation of inflammation, SPMs actively orchestrate its termination — limiting neutrophil infiltration, promoting macrophage efferocytosis of apoptotic cells, and restoring tissue homeostasis.[1]
The discovery overturned a foundational dogma. Inflammation has two halves: initiation (prostaglandins, leukotrienes, cytokines) and resolution (SPMs). When resolution fails, acute inflammation does not simply persist — it transforms into the chronic, non-resolving inflammation that underlies atherosclerosis, neurodegeneration, periodontitis, inflammatory bowel disease, and metabolic syndrome.[2]
How Resolvin Biosynthesis from EPA and DHA Works
Substrate Mobilization: SPM biosynthesis begins with the release of EPA and DHA from membrane phospholipids by phospholipase A2. Without adequate dietary intake of these omega-3 substrates, the entire pathway is constrained — a key reason that low EPA/DHA status is increasingly viewed as a state of latent resolution deficiency rather than mere nutritional inadequacy.[1]
Sequential Lipoxygenase Action: Free EPA and DHA are converted to SPMs through sequential oxygenation by lipoxygenase enzymes — primarily 15-LOX and 5-LOX, with cell-type-specific contributions from 12-LOX. E-series resolvins arise when EPA is acted upon by aspirin-acetylated COX-2 or cytochrome P450, generating 18R-HEPE, which 5-LOX then converts to RvE1. D-series resolvins, protectins, and maresins arise from DHA through analogous pathways involving 17-HDHA and 14-HDHA intermediates.[1][3]
Receptor-Mediated Signaling: SPMs act through specific G-protein-coupled receptors. RvE1 signals via ChemR23 (ERV1) and antagonizes BLT1; RvD1 binds ALX/FPR2 and GPR32; MaR1 signals through LGR6. Engagement of these receptors triggers a stereotyped resolution program: cessation of neutrophil recruitment, polarization of macrophages toward the reparative M2 phenotype, enhanced clearance of apoptotic neutrophils (efferocytosis), and counter-regulation of NF-κB-driven cytokine production.[2]
Aspirin-Triggered Epimers: Low-dose aspirin acetylates COX-2 without abolishing its catalytic activity, redirecting it to produce 17R-epimers of D-series resolvins (aspirin-triggered RvDs). These epimers are more resistant to enzymatic inactivation and may explain a portion of aspirin’s cardioprotective effect beyond platelet inhibition.[3]
Clinical Evidence
Cardiovascular Disease: Human atherosclerotic plaques exhibit a marked imbalance between pro-inflammatory leukotriene B4 and pro-resolving lipoxin A4 and resolvins, with vulnerable plaques showing the greatest SPM deficit. In a study of carotid endarterectomy specimens, plaques from symptomatic patients had significantly lower RvD1 content than stable plaques, and restoring SPM signaling in murine models stabilizes lesions and reduces necrotic core formation.[4]
Periodontitis and Tissue Regeneration: RvE1 administration in animal models of periodontitis not only halts bone loss but reverses it — one of the first demonstrations that a pro-resolving mediator can drive tissue regeneration rather than merely arresting damage. This has reframed periodontal disease as a failure of resolution rather than excessive immune activation.[2]
Neuroinflammation: Neuroprotectin D1 (NPD1/PD1), a DHA-derived SPM, is produced in the retina and brain in response to oxidative and ischemic stress. NPD1 promotes neuronal survival, downregulates pro-apoptotic Bax and Bad, and upregulates anti-apoptotic Bcl-2 family proteins. Reduced NPD1 has been documented in Alzheimer’s disease hippocampus, supporting a resolution-failure hypothesis of neurodegeneration.[5]
Pain and Tissue Repair: Maresin 1 (MaR1) has demonstrated potent analgesic and tissue-reparative effects in preclinical models, accelerating macrophage phenotype switching and resolving inflammatory pain at doses orders of magnitude below those required for conventional NSAIDs.[3]
Why SPM Deficiency Drives Chronic Disease
Substrate Limitation: Modern Western diets are profoundly EPA- and DHA-deficient, with omega-6 to omega-3 ratios commonly exceeding 15:1 compared to ancestral ratios near 1:1. Because SPMs cannot be synthesized without their parent fatty acids, low omega-3 intake creates a structural ceiling on resolution capacity — chronic inflammation in this context is partly a substrate problem.[1]
Enzymatic Dysregulation: Aging, hyperglycemia, and oxidative stress impair lipoxygenase function and shift the SPM-to-leukotriene ratio toward sustained inflammation. In type 2 diabetes, plasma SPM concentrations are reduced and correlate inversely with HbA1c, suggesting metabolic disease both causes and is perpetuated by resolution failure.[4]
NSAID Interference: Non-selective COX inhibitors and corticosteroids, while suppressing inflammation initiation, paradoxically blunt resolution by reducing the substrates for aspirin-triggered lipoxin and resolvin pathways. This may partly explain the delayed tissue healing observed with chronic NSAID use.[2]
Safety Profile and Therapeutic Considerations
SPMs are endogenous molecules acting at picomolar to nanomolar concentrations, and unlike immunosuppressive agents they do not compromise host defense — in fact, they enhance bacterial clearance by promoting macrophage phagocytosis. Preclinical work consistently shows that SPM administration shortens infection duration rather than prolonging it, a critical pharmacological distinction from steroids and biologics.[2]
From a translational standpoint, the most accessible intervention remains optimizing EPA and DHA status through marine omega-3 intake. Human trials of high-dose EPA/DHA supplementation demonstrate dose-dependent increases in circulating 18-HEPE, 17-HDHA, and 14-HDHA — the immediate precursors of E-resolvins, D-resolvins/protectins, and maresins respectively — confirming that dietary omega-3 loading genuinely augments endogenous SPM biosynthesis.[5]
SPMs vs Conventional Anti-Inflammatory Approaches
Versus NSAIDs: NSAIDs inhibit COX enzymes upstream, suppressing both pro-inflammatory prostaglandins and the substrates needed for certain resolution pathways. SPMs act downstream to actively terminate inflammation without blocking initiation, preserving the host’s ability to mount appropriate acute responses.
Versus Corticosteroids: Glucocorticoids broadly suppress immune function and impair wound healing. SPMs selectively redirect immune cell behavior — switching off neutrophil recruitment while enhancing macrophage clearance functions — without systemic immunosuppression.
Versus Biologic Cytokine Blockade: Anti-TNF and anti-IL-6 biologics neutralize single cytokines but do not restore resolution programming. A patient on long-term TNF blockade may have suppressed inflammation yet retain a fundamentally non-resolving phenotype. SPM-based strategies aim to repair the resolution circuitry itself rather than mask its failure.
The reframing is consequential: chronic inflammatory disease is not simply too much inflammation but too little resolution. Restoring SPM biosynthesis — through adequate EPA/DHA substrate, judicious low-dose aspirin in appropriate populations, and emerging synthetic SPM analogs — represents a fundamentally different therapeutic paradigm from suppression.
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Serhan CN, Levy BD. “Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.” Journal of Clinical Investigation. 2018;128(7):2657-2669.
- Serhan CN, Chiang N, Dalli J. “The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.” Seminars in Immunology. 2015;27(3):200-215.
- Fredman G, Hellmann J, Proto JD, et al. “An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.” Nature Communications. 2016;7:12859.
- Bazan NG, Molina MF, Gordon WC. “Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases.” Annual Review of Nutrition. 2011;31:321-351.
